Capstone Holding Corp. lowers convertible note conversion price to $1.00
Caroline Loew, the Chief Executive Officer of Mural Oncology plc (NASDAQ:MURA), recently sold a portion of her shares in the company, according to a recent SEC filing. The transaction, which took place on March 4, 2025, involved the sale of 4,313 ordinary shares at a weighted average price of $3.36 per share, amounting to a total value of $14,491. The sale comes as MURA’s stock has declined 9.5% over the past week, though InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $13 and $18.
The sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted to Loew. These shares were automatically sold, as stipulated in a restricted stock unit agreement that includes a binding contract under Rule 10b5-1, and did not represent a discretionary trade by Loew. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 7.38x.
In addition to the sale, Loew acquired 72,275 ordinary shares on March 3, 2025, through the vesting of RSUs, at no cost. Furthermore, she was also granted stock options for 134,225 shares, which are scheduled to vest over the coming years, contingent on her continued service with the company.
Following these transactions, Loew’s total direct ownership in Mural Oncology stands at 305,590 shares.
In other recent news, Mural Oncology has garnered attention with Jones Trading initiating coverage on the company with a Buy rating and a price target of $16. The firm’s analysis is optimistic about Mural Oncology’s future, particularly due to anticipated positive interim Phase 3 data expected in the first half of 2025. This data is projected to influence investor sentiment positively, especially concerning the company’s IL-2 drug development program. Mural Oncology’s financial standing is strong, with approximately $175 million in cash reserves reported at the end of the third quarter of 2024. This financial position is expected to support the company’s operations until the first quarter of 2026. Jones Trading highlights two major catalysts for Mural Oncology in the first half of 2025, suggesting a favorable risk/reward scenario for investors. The firm’s confidence in Mural Oncology is based on the potential to overcome past challenges in IL-2 drug development. The analysis from Jones Trading indicates that these developments could reshape market perceptions of Mural Oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.